Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Viral And Non-Viral Vector Manufacturing Market Growth From $12.4 Billion In 2026 To $26.82 Billion By 2030 At A CAGR Of 21.3%
The market for both viral and non-viral vector manufacturing has experienced substantial expansion lately. Projections indicate a rise from $10.28 billion in 2025 to $12.4 billion in 2026, demonstrating a compound annual growth rate of 20.7%. Factors contributing to this growth during the preceding period include progress in gene therapy investigations, an uptick in clinical trial engagements, the scaling up of biopharmaceutical production capabilities, escalating demand for viral vectors in cancer treatments, and the presence of specialized manufacturing proficiency.
The market for manufacturing both viral and non-viral vectors is poised for substantial expansion over the coming years, projected to reach $26.83 billion by 2030, with a compound annual growth rate of 21.3%. This upward trajectory is fueled by several key factors, including the increasing commercial viability of gene and cell therapies, a surge in investment directed towards vaccine research and development, the broadening of collaborations with Contract Development and Manufacturing Organizations (CDMOs), an intensified emphasis on developing manufacturing processes that are both scalable and adaptable, and a greater number of regulatory approvals for sophisticated therapeutic approaches. Key developments anticipated during this period encompass the scaling up of viral vector production capabilities, a growing need for non-viral delivery mechanisms, the wider acceptance of modular manufacturing systems, the expansion of outsourced vector production services, and a strengthened commitment to standardizing processes and ensuring rigorous quality control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
Viral And Non-Viral Vector Manufacturing Market Growth Factors Supporting Long-Term Expansion
The increase in the volume of clinical trials is anticipated to be a significant catalyst for the expansion of the viral and non-viral vector manufacturing sectors. Clinical trials, which are crucial research endeavors involving human subjects to assess the safety, effectiveness, and potential adverse reactions of medical interventions, treatments, or pharmaceuticals, rely heavily on the production of these vectors. The manufacturing of viral and non-viral vectors plays a vital role in facilitating gene therapy clinical trials by supplying the essential components for delivering therapeutic genes to participants, while concurrently ensuring the integrity, quality, and manufacturability of these delivery systems across all stages of research. Illustratively, data from ClinicalTrials.gov, a digital repository managed by the US National Library of Medicine and dedicated to tracking clinical studies, revealed that by the close of 2022, there were 437,515 registered clinical trials, of which 56,561 had reached completion. This upward trend continued into 2023, with figures reaching 476,626 registered trials and 61,504 completed trials as of December 20th, highlighting a consistent rise in both new registrations and completed studies. Consequently, the burgeoning number of clinical trials directly fuels the demand and growth within the viral and non-viral vector manufacturing industries.
Viral And Non-Viral Vector Manufacturing Market Segment Analysis: What Are The Major Market Categories?
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
Viral And Non-Viral Vector Manufacturing Market Industry Trends Shaping Future Revenue Growth
In the realm of viral and non-viral vector production, leading enterprises are prioritizing strategic alliances to augment their market returns. These collaborative efforts in the viral and non-viral vector manufacturing sector unite biopharmaceutical firms, Contract Development and Manufacturing Organizations (CDMOs), academic centers, and technological innovators, all aiming to refine the effectiveness, security, and scalability of non-viral vector creation and manufacturing processes. A notable illustration occurred in September 2023 when NecstGen, a CDMO based in the Netherlands offering extensive services to all cell and gene therapy developers, joined forces with ProteoNic BioSciences, a Dutch technology firm specializing in the creation of intricate therapeutic proteins, introducing ProteoNic’s 2G UNic advanced vector technology. The effective implementation of this innovation has significantly advanced the development of lentiviral (LV) vectors, elevating functional viral particle titers and directly improving operational efficiency, which in turn makes therapies more economical and accessible. This adaptable technology finds utility in a variety of uses, encompassing the production of viral vectors for gene therapy, the development of mRNA therapeutics, and the generation of transient proteins. By pushing forward the manufacturing technology for both AAV and LV viral vectors, catering to transient systems and robust producer cell lines alike, this advancement holds promise for improving viral vector manufacturing in gene therapies and non-vector related procedures, presenting prospective advantages across a wide spectrum of applications.
Viral And Non-Viral Vector Manufacturing Market Leading Companies Driving Competitive Growth
Major companies operating in the viral and non-viral vector manufacturing market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Access The Complete Viral And Non-Viral Vector Manufacturing Market Report:
Viral And Non-Viral Vector Manufacturing Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the viral and non-viral vector manufacturing market in 2025. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
